Visual abstract
Most viewed in the last 7 days from JAMA: The addition of simvastatin plus rifaximin to standard therapy does not improve outcomes in patients with decompensated liver cirrhosis.
https://ja.ma/3EE33uQ
Visual abstract
Most viewed in the last 7 days from JAMA: The addition of simvastatin plus rifaximin to standard therapy does not improve outcomes in patients with decompensated liver cirrhosis.
https://ja.ma/3EE33uQ
Just published in @jama.com: Simvastatin and Rifaximin in Decompensated Cirrhosis. @salvatore-piano.bsky.social @juanabraldes.bsky.social @easlnews.bsky.social @bavenocoop.bsky.social #liversky jamanetwork.com/journals/jam...
06.02.2025 10:06 — 👍 2 🔁 0 💬 0 📌 0